Bibliographic citations
Ramírez, G., (2024). Uso de inhibidores SGLT2 como factor nefroprotector en pacientes con Diabetes Mellitus tipo 2: Revisión Sistemática y Meta-Análisis. [Tesis, Universidad Privada Antenor Orrego]. https://hdl.handle.net/20.500.12759/23171
Ramírez, G., Uso de inhibidores SGLT2 como factor nefroprotector en pacientes con Diabetes Mellitus tipo 2: Revisión Sistemática y Meta-Análisis. [Tesis]. PE: Universidad Privada Antenor Orrego; 2024. https://hdl.handle.net/20.500.12759/23171
@misc{renati/381065,
title = "Uso de inhibidores SGLT2 como factor nefroprotector en pacientes con Diabetes Mellitus tipo 2: Revisión Sistemática y Meta-Análisis.",
author = "Ramírez Chávez, Gianella Elva Carolina",
publisher = "Universidad Privada Antenor Orrego",
year = "2024"
}
To evaluate whether the use of SGLT2 inhibitors is a nephroprotective factor in adult patients with type 2 diabetes mellitus. Methods: This systematic review and meta-analysis study followed the PRISMA 2020 guidelines. A strategic search was performed in four databases: Pudmed, Web of Science, Scopus and Embase. Randomized clinical trials were incorporated, articles were stored and selected in Rayyan software: subsequently data extraction was performed in Microsoft Excel 2019. Risk of bias was analyzed using the RoB 2.0 tool of the Cochrane Collaboration. Meta-analysis was performed using the free software RStudio; the evaluation of the quality and certainty of evidence was performed in the GRADEpro program. Results: Twelve randomized clinical trials were included in the meta-analysis. At 12 weeks, no significant difference was found with respect to mean glomerular filtration rate (GFR) in the intervention group compared to placebo (MD: 0.78; 95% CI: -1.36 to 2.92; I2=0%; p=0.43) However, SGLT2 inhibitors significantly reduced the progressive loss of GFR at 2 years (RR: 0.66; 95% CI: 0.49 to 0.89; p<0.001) as well at 3, 4 and 7 years. Conclusion: SGLT2 inhibitors significantly decreased the progressive loss of GFR compared to placebo, with longer treatment duration. Likewise, systolic and diastolic blood pressure had a beneficial effect, thus reducing cardiovascular risk; it also reduced the percentage of HbA1c and body weight.
This item is licensed under a Creative Commons License